At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
ALXN1910 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants
In Brief
A Phase 1 clinical trial evaluating ALXN1910 and Placebo for Healthy. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1910 subcutaneous (SC) and SAD of ALXN1910 intravenous (IV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartApr 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedApr 1, 2022
Enrollment StartApr 12, 2022
Primary CompletionFeb 7, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.3 years ago
Interventions
ALXN1910drug
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Placebodrug
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.